-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $219

Benzinga·08/01/2025 15:25:37
Listen to the news
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $208 to $219.